RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer's disease.

Cui GH, Guo HD, Li H, Zhai Y, Gong ZB, Wu J, Liu JS, Dong YR, Hou SX, Liu JR. · 2019

Read RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer's disease. by Cui GH, Guo HD, Li H, Zhai Y, Gong ZB, Wu J, Liu JS, Dong YR, Hou SX, Liu JR. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6515654.txt.

Introduction

Cui and co-authors test brain-targeted exosomes in a mouse model of Alzheimer's disease. Their study appeared in Immunity & Ageing. Exosomes from mesenchymal stem cells can ease memory loss in such models. But injected exosomes mostly end up in other organs. Few reach the brain.

The team tagged the exosomes with the RVG peptide. That peptide targets the central nervous system. Tagged exosomes reached the cortex and hippocampus better after vein injection. In APP/PS1 mice, plaque deposits and amyloid-beta levels fell sharply. Astrocyte activation also dropped. Treated mice scored better in the Morris water maze. Inflammatory signals fell, while anti-inflammatory factors rose.

Catalog record

CREATORCui GH, Guo HD, Li H, Zhai Y, Gong ZB, Wu J, Liu JS, Dong YR, Hou SX, Liu JR.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6515654

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease By Guo-hong Cui, Hai-dong Guo, Han Li, Yu Zhai, Zhang-bin Gong, Jing Wu, Jian-sheng Liu, You-rong Dong, Shuang-xing Hou, Jian-ren Liu Published in: Immunity & Ageing : I & A DOI: 10.1186/s12979-019-0150-2 ABSTRACT Background Exosomes are lipid-bilayer enclosed nano-sized vesicles that transfer functional cellular proteins, mRNA and miRNAs. Mesenchymal stem cells (MSCs) derived exosomes have been demonstrated to prevent memory deficits in the animal model of Alzheimer’s disease (AD). However, the intravenously injected exosomes could be abundantly tracked in other organs except for the targeted regions in the brain. Here, we proposed the use of central nervous system-specific rabies viral glycoprotein (RVG) peptide to target intravenously-infused exosomes derived from MSCs (MSC-Exo) to the brain of transgenic APP/PS1 mice. MSC-Exo were conjugated with RVG through a DOPE-NHS linker. Results RVG-tagged MSC-Exo exhibited improved targeting to the cortex and hippocampus after being administered intravenously. Compared with the group administered MSC-Exo, in the group administered RVG-conjugated MSC-Exo (MSC-RVG-Exo) plaque deposition and Aβ levels were sharply decreased and activation of astrocytes was obviously reduced. The brain targeted exosomes derived from MSCs was better than unmodified exosomes to improve cognitive function in APP/PS1 mice according to Morris water maze test. Additionally, although MSC-Exo injected intravenously reduced the expression of pro-inflammatory mediators TNF-α, IL-β, and IL-6, but the changes of anti-inflammatory factors IL-10 and IL-13 were not obvious. However, administration of MSC-RVG-Exo significantly reduced the levels of TNF-α, IL-β, and IL-6 while significantly raised the levels of IL-10, IL-4 and IL-13. Conclusions Taken together, our results demonstrated a novel method for increasing delivery of exosomes for treatment of AD. By targeting exosomes to the cortex and hippocampus of AD mouse, there was a significant improvement in learning and memory capabilities with reduced plaque deposition and Aβ levels, and normalized levels of inflammatory cytokines. Electronic supplementary material The online version of this article (10.1186/s12979-019-0150-2) contains supplementary material, which is available to authorized users. INTRODUCTION Alzheimer’s disease (AD), the most prevalent type of dementia, is characterized by excessive deposition of amyloid-β peptide (Aβ) and neurofibrillary tangles, which cause neuronal dysfunction and loss ultimately [1]. Rapid advances in stem-cell biology have provided a promising novel therapy for AD. A huge volume of data has demonstrated that stem cell transplantation improved cognition, learning, and memory by replacement of damaged neurons, release of neurotrophic factors, and clearance of Aβ plaques [2]. Our previous study showed that transplantation of neural stem cells (NSCs) improved cognitive function in an Aβ-infused model of AD via neuron differentiation and paracrine action [3]. In addition, chronic inflammation is involved in the pathogenesis of AD, and mesenchymal stem cells (MSCs) appear to exert anti-inflammatory effects by modulating the balance of proinflammatory and anti-inflammatory factors [4]. Recent data showed that stem cell-derived exosomes might be a new strategy for several central nervous system (CNS) disorders. The exosomes are small biological lipid membrane vesicles with diameters ranging from 30~100 nm found in various cell types and the major mediators of intercellular communication through shuttling biologically active molecules to targeted recipient cells [5]. The transfer of exosomal cargo provides a rationale for the many reported stem cell-based therapeutic outcomes. For example, MSC-derived exosomes benefit neurite remodeling and functional recovery after stroke by mediating the miR-133b transfer to astrocytes and neurons [6]. Moreover, it has been reported that human adipose MSC-derived exosomes contain functional neprilysin, a major Aβ-degrading enzyme and, thus, have the potential to reduce the pathological accumulation of Aβ in AD [7]. In our previous study, the expression of miR-21 in MSC-derived exosomes was involved in modulation of the inflammatory response and improvement of cognitive function in an APP/PS1 double transgenic model of AD [8]. In addition, miRNA-181c expression in MSC-exosomes reduced burn-induced inflammation by down-regulating the toll-like receptor 4 signaling pathway [9]. Although the exosomes have the ability to cross the blood-brain barrier (BBB), a recent dynamic biodistribution study of exosomes revealed a significant amount of exosomes accumulated in the spleen and liver, and very limited exosomes signals were detected in the brain after systemic administration [10]. Thus, we propose that surface modified stem cell-derived exosomes targeted to the brain are agents with superior therapeutic potential to prevent memory deficits in AD. The CNS-specific rabies viral glycoprotein (RVG) peptide interacts specifically with the acetylcholine receptor to enable viral entry into neuronal cells [11]. Lydia et al. acquired targeted exosomes by engineering the exosomes to express RVG peptide and intravenous injection of these engineered exosomes delivered siRNA specifically to the mouse brain [12]. Furthermore, the targeted RVG exosomes loaded with opioid receptor Mu (MOR) siRNA was a potential novel strategy for the treatment of morphine relapse by down-regulating MOR expression levels [13]. In this study, we created brain-targeting exosomes derived from MSCs, through the use of peptide RVG, to increase the efficacy of intravenously delivered exosomes. Then the RVG modified exosomes were intravenously administrated to APP/PS1 transgenic mice through the tail vein to observe its therapeutic effect through Morris water maze test. Plaque deposition and Aβ accumulation were detected through Thioflavin-S staining and ELISA, respectively. Additionally, the expression of pro-inflammatory and anti-inflammatory cytokines were determined through quantitative real-time polymerase chain reaction (qRT-PCR) and ELISA. This study presented a feasible way to develop exosomes targeted to the brain for treating AD. MATERIALS AND METHODS Animals APP/PS1 double transgenic mice, B6C3-Tg (APPswe, PSEN1dE9) 85Dbo/J (original species No. 004462), were obtained from Jackson Laboratories (Bar Harbor, ME). The transgenic mice were maintained on a standard 12-h light/dark cycle at a constant temperature, with free access to food and water. This study was approved by the animal ethics committee of Shanghai University of TCM and the Animal Research Committee of Shanghai. All of the protocols were based on the “Guide for the Care and Use of Laboratory Animals” of the National Institutes of Health (USA) and efforts were made to minimize the number of animals used and any discomfort experienced. Isolation and culture of MSCs To isolate bone marrow, mice were killed by cervical dislocation and the hind limbs were dissected from the trunk of the body with care not to damage the femur. Bisect each hind limb by cutting through the knee joint. Remove the muscle and connective tissue from both the tibia and the femur. Cut the ends of the tibia and femur just below the end of the marrow cavity and flush the marrow using a 27-gauge needle attached to a 10-ml syringe containing Dulbecco’s Modified Eagle’s medium (DMEM, Gibco, San Diego, USA). The medium with bone marrow was centrifuged and the cell pellet was resuspended in DMEM supplemented with 15% fetal bovine serum (FBS, Gibco) and then cultured at 37 °C under a 5% CO2 atmosphere. The medium was changed at 48 h. For subculture, cells were detached with 0.25% trypsin-ethylene diamine tetra-acetic acid (Gibco Invitrogen, USA) and seeded in DMEM with 15% FBS [14]. The characterization of cell surface markers (CD29, CD44, CD45) were detected through immunofluorescence staining. The cells were incubated with the primary antibodies (1:100, Abcam, USA) overnight at 4 °C after being fixed with 4% paraformaldehyde. Then the cells were labeled with Alexa Flour

Read the complete text